We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Crossing the line.
- Authors
Ratner, Mark
- Abstract
The article focuses on the determination of the U.S. government to continue with its efforts to prevent drug companies from making fraudulent product claims by using new theories of liability and imposing stiffer penalties. The move came amidst the emergence of high-profile fraud settlements involving pharmaceutical, biotechnology and medical device companies. It cites recent fraud cases and the resulting terms of the corporate integrity agreement (CIA) between the company and the government.
- Subjects
UNITED States; FRAUD prevention; LEGAL liability; INDUSTRIES; PHARMACEUTICAL industry; BIOTECHNOLOGY industries; FINES (Penalties); MEDICAL equipment industry; LEGAL settlement
- Publication
Nature Biotechnology, 2010, Vol 28, Issue 12, p1232
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt.1726